Spruce Biosciences SPRB
NASDAQ SPRB
$48.58 +1.31 (+2.77%)
At close: Sep 30, 2026 · 4:00 PM EDT

Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024)

Updated

Spruce Biosciences' Current Deferred Revenue came in at $700,000 for Q3 2024, down 91.0% from $7.8 million a year earlier and down 46.2% from the prior quarter.

Analysis

Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024) Analysis & Trends

At the end of FY2023, Spruce Biosciences' Current Deferred Revenue was $4.91 million.

  • Year-over-year, Current Deferred Revenue has declined for three consecutive quarters.
  • Business Quant data shows SPRB's Current Deferred Revenue at $1.3 million (Q2 2024), $2.91 million (Q1 2024) and $4.91 million (Q4 2023) in the three quarters before Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Spruce Biosciences 130.13 Mn 130.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 700,000.00
Jun 30, 2024 1.30 Mn
Mar 31, 2024 2.91 Mn
Dec 31, 2023 4.91 Mn
Sep 30, 2023 7.80 Mn
Jun 30, 2023 8.10 Mn
Mar 31, 2023 9.21 Mn
API Access

Spruce Biosciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SPRB&period=max&api_key=YOUR_API_KEY